PDE isoenzymes as targets for anti-asthma drugs

Phophodiesterase (PDE) isoenzyme profiles of human cell preparations and tissues have been analysed by a semiquantitative method using selective PDE inhibitors and activators. Neutrophils, eosinophils and monocytes contain PDE IV exclusively. Lymphocytes, alveolar macrophages and endothelial cells contain PDE IV and PDE III, and in addition, PDE I is measured in macrophages and PDE II in endothelial cells. These basal cell-specific PDE isoenzyme profiles appear to be modified by: 1) substrate concentration; 2) kinase-dependent phosphorylation; and 3) regulated rate of synthesis. Therefore, PDE isoenzyme profiles represent dynamic patterns, which apparently adapt to pathological and environmental conditions. In parallel functional studies, the influence of mono-selective (rolipram, PDE IV; motapizone, PDE III), dual-selective (zardaverine) and non-selective (theophylline) PDE inhibitors were compared. Corresponding to isoenzyme analysis, it was demonstrated that both PDE III and PDE IV have to be inhibited for complete suppression of either tumour necrosis factor-alpha (TNF-alpha) release from macrophages, or lymphocyte proliferation (PDE III/IV cells). In eosinophils (PDE IV cells) platelet-activating factor (PAF)-induced chemotaxis or C5a-stimulated degranulation are only weakly inhibited by rolipram alone. After addition of a beta 2-agonist, however, the efficacy of rolipram is enhanced due to concomitant influence of synthesis and breakdown of cyclic adenosine monophosphate (cAMP). Theophylline inhibits PDE isoenzyme activities and functions of inflammatory cells with similar potency, and exhibits higher functional efficacy as compared to rolipram.

This article has been cited by other articles:

				D. Peter, S. L. C. Jin, M. Conti, A. Hatzelmann, and C. Zitt Differential Expression and Function of Phosphodiesterase 4 (PDE4) Subtypes in Human Primary CD4+ T Cells: Predominant Role of PDE4D J. Immunol., April 15, 2007; 178(8): 4820 - 4831. [Abstract] [Full Text] [PDF]

				C. S. Moore, N. Earl, R. Frenette, A. Styhler, J. A. Mancini, D. W. Nicholson, A. L. O. Hebb, T. Owens, and G. S. Robertson Peripheral Phosphodiesterase 4 Inhibition Produced by 4-[2-(3,4-Bis-difluoromethoxyphenyl)-2-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)-phenyl]-ethyl]-3-methylpyridine-1-oxide (L-826,141) Prevents Experimental Autoimmune Encephalomyelitis J. Pharmacol. Exp. Ther., October 1, 2006; 319(1): 63 - 72. [Abstract] [Full Text] [PDF]

				S. B Karish and J. M Gagnon The Potential Role of Roflumilast: The New Phosphodiesterase-4 Inhibitor Ann. Pharmacother., June 1, 2006; 40(6): 1096 - 1104. [Abstract] [Full Text] [PDF]

				M. A. Giembycz Phosphodiesterase-4: Selective and Dual-Specificity Inhibitors for the Therapy of Chronic Obstructive Pulmonary Disease Proceedings of the ATS, November 1, 2005; 2(4): 326 - 333. [Abstract] [Full Text] [PDF]

				W.-J. Luo, X. Ling, and R.-M. Huang Effects of aminophylline on cytokines and pulmonary function in patients undergoing valve replacement Eur. J. Cardiothorac. Surg., May 1, 2004; 25(5): 766 - 771. [Abstract] [Full Text] [PDF]

				R. K. Kumar, C. Herbert, P. S. Thomas, L. Wollin, R. Beume, M. Yang, D. C. Webb, and P. S. Foster Inhibition of Inflammation and Remodeling by Roflumilast and Dexamethasone in Murine Chronic Asthma J. Pharmacol. Exp. Ther., October 1, 2003; 307(1): 349 - 355. [Abstract] [Full Text] [PDF]

				T. Kohyama, X. Liu, Y. K. Zhu, F.-Q. Wen, H. J. Wang, Q. Fang, T. Kobayashi, and S. I. Rennard Phosphodiesterase 4 Inhibitor Cilomilast Inhibits Fibroblast-Mediated Collagen Gel Degradation Induced by Tumor Necrosis Factor-{alpha} and Neutrophil Elastase Am. J. Respir. Cell Mol. Biol., October 1, 2002; 27(4): 487 - 494. [Abstract] [Full Text] [PDF]

				T. Kohyama, X. Liu, F.-Q. Wen, Y. K. Zhu, H. Wang, H. J. Kim, H. Takizawa, L. B. Cieslinski, M. S. Barnette, and S. I. Rennard PDE4 Inhibitors Attenuate Fibroblast Chemotaxis and Contraction of Native Collagen Gels Am. J. Respir. Cell Mol. Biol., June 1, 2002; 26(6): 694 - 701. [Abstract] [Full Text] [PDF]

				B. J. De Witt, I. N. Ibrahim, E. Bayer, A. M. Fields, T. A. Richards, R. E. Banister, and A. D. Kaye An Analysis of Responses to Levosimendan in the Pulmonary Vascular Bed of the Cat Anesth. Analg., June 1, 2002; 94(6): 1427 - 1433. [Abstract] [Full Text] [PDF]

				G. Rena, F. Begg, A. Ross, C. MacKenzie, I. McPhee, L. Campbell, E. Huston, M. Sullivan, and M. D. Houslay Molecular Cloning, Genomic Positioning, Promoter Identification, and Characterization of the Novel Cyclic AMP-Specific Phosphodiesterase PDE4A10 Mol. Pharmacol., April 16, 2001; 59(5): 996 - 1011. [Abstract] [Full Text]

				M. Aoki, M. Kobayashi, J. Ishikawa, Y. Saita, Y. Terai, K. Takayama, K. Miyata, and T. Yamada A Novel Phosphodiesterase Type 4 Inhibitor, YM976 (4-(3-Chlorophenyl)-1,7-diethylpyrido[2,3-d]pyrimidin-2(1H)-one), with Little Emetogenic Activity J. Pharmacol. Exp. Ther., October 1, 2000; 295(1): 255 - 260. [Abstract] [Full Text]

				I. McPhee, S. J. Yarwood, G. Scotland, E. Huston, M. B. Beard, A. H. Ross, E. S. Houslay, and M. D. Houslay Association with the SRC Family Tyrosyl Kinase LYN Triggers a Conformational Change in the Catalytic Region of Human cAMP-specific Phosphodiesterase HSPDE4A4B. CONSEQUENCES FOR ROLIPRAM INHIBITION J. Biol. Chem., April 23, 1999; 274(17): 11796 - 11810. [Abstract] [Full Text] [PDF]

				S. Uhlig, R. L. Featherstone, H.-D. Held, R. Nüsing, C. Schudt, and A. Wendel Attenuation by Phosphodiesterase Inhibitors of Lipopolysaccharide-Induced Thromboxane Release and Bronchoconstriction in Rat Lungs J. Pharmacol. Exp. Ther., December 1, 1997; 283(3): 1453 - 1459. [Abstract] [Full Text]

				T. J. TORPHY Phosphodiesterase Isozymes . Molecular Targets for Novel Antiasthma Agents Am. J. Respir. Crit. Care Med., February 1, 1997; 157(2): 351 - 370. [Full Text]